NYSE:TMBR

Timber Pharmaceuticals - TMBR Stock Forecast, Price & News

$0.09

-0.01 (-5.63%)

(As of 10/5/2022 04:31 PM ET)

Add

Compare

Today's Range: $0.09
▼
$0.10
50-Day Range: $0.09
▼
$0.23
52-Week Range: $0.08
▼
$0.87

Volume: 10.41 million shs
Average Volume: 5.56 million shs
Market Capitalization: $12.00 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.00

Timber Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,003.8% Upside
$1.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.15
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.17) to ($0.09) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

712th out of 1,072 stocks

Pharmaceutical Preparations Industry

344th out of 534 stocks

3.5

Analyst's Opinion

Consensus Rating
Timber Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.00, Timber Pharmaceuticals has a forecasted upside of 1,003.8% from its current price of $0.09.
Amount of Analyst Coverage
Timber Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for TMBR.

0.0

Dividend Strength

Dividend Yield
Timber Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Timber Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TMBR.

2.9

News and Social Media Coverage

News Sentiment
Timber Pharmaceuticals has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Timber Pharmaceuticals this week, compared to 0 articles on an average week.
Search Interest
Only 6 people have searched for TMBR on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Timber Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -58% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Timber Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.11% of the stock of Timber Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 5.78% of the stock of Timber Pharmaceuticals is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Timber Pharmaceuticals are expected to grow in the coming year, from ($0.17) to ($0.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Timber Pharmaceuticals is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Timber Pharmaceuticals is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Timber Pharmaceuticals has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Timber Pharmaceuticals (NYSE:TMBR) Stock

Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.

Receive TMBR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Timber Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TMBR Stock News Headlines

October 3, 2022 | msn.com

1TMBR : Why Timber Pharmaceuticals Shares Are Getting Hammered

October 3, 2022 | finance.yahoo.com

Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering

September 14, 2022 | finance.yahoo.com

Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis

August 29, 2022 | finance.yahoo.com

Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing Deficiency

August 29, 2022 | finance.yahoo.com

Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV Congress

August 26, 2022 | finance.yahoo.com

Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology

August 11, 2022 | finance.yahoo.com

Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2022 Financial Results

August 11, 2022 | benzinga.com

Thinking about buying stock in Invitae, Timber Pharmaceuticals, Matterport, Nio, or Bed Bath & Beyond?

August 8, 2022 | finance.yahoo.com

Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering

August 8, 2022 | finance.yahoo.com

Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering

August 4, 2022 | uk.finance.yahoo.com

Timber Pharmaceuticals Announces Pricing of $8.0 Million Public Offering

August 4, 2022 | finance.yahoo.com

Timber Pharmaceuticals Announces Pricing of $8.0 Million Public Offering

June 23, 2022 | seekingalpha.com

Timber begins enrolling in late-stage trial of topical drug for rare skin disorder

June 23, 2022 | finance.yahoo.com

Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis

May 31, 2022 | seekingalpha.com

Timber Pharma soars on FDA Breakthrough Designation for skin disease therapy

May 31, 2022 | finance.yahoo.com

Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis

May 14, 2022 | seekingalpha.com

Timber Pharmaceuticals GAAP EPS of -$0.05

May 12, 2022 | finance.yahoo.com

Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial Results

May 2, 2022 | benzinga.com

HC Wainwright & Co. Maintains Buy on Timber Pharmaceuticals, Lowers Price Target to $1.5

April 28, 2022 | seekingalpha.com

Timber Pharma jumps after FDA fast track nod for TMB-001 to treat ichthyosis skin diseases

March 1, 2022 | finanznachrichten.de

The Investor Summit: Timber Pharmaceuticals: Invitation to the Q1 Virtual Investor Summit

February 28, 2022 | finance.yahoo.com

Timber Pharmaceuticals: Invitation to the Q1 Virtual Investor Summit

February 3, 2022 | seekingalpha.com

Timber plans phase 3 trial of TMB-001 for skin disease following meeting with FDA

December 20, 2021 | finance.yahoo.com

When Should You Buy Adbri Limited (ASX:ABC)?

November 17, 2021 | finance.yahoo.com

Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive TMBR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Timber Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TMBR Company Calendar

Last Earnings: 8/11/2022
Today: 10/05/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:TMBR
CUSIP: N/A
CIK: 1504167
Web: www.timberpharma.com
Phone: (914) 205-3481
Fax: N/A
Employees: 5
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $1.00
High Stock Price Forecast: $1.00
Low Stock Price Forecast: $1.00
Forecasted Upside/Downside: +1,003.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.33)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,640,000.00
Net Margins: -1,274.17%
Pretax Margin: -3,407.04%
Return on Equity: -228.75%
Return on Assets: -121.90%

Debt

Debt-to-Equity Ratio: 1.30
Current Ratio: 1.41
Quick Ratio: 1.41

Sales & Book Value

Annual Sales: $890,000.00
Price / Sales: 13.48
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.21 per share
Price / Book: 0.43

Miscellaneous

Outstanding Shares: 132,451,000
Free Float: 130,981,000
Market Cap: $12.00 million
Optionable: Not Optionable
Beta: 0.19

Key Executives

Mr. John Koconis M.B.A. (Age 52)
Chairman, CEO & Pres
Comp: $508.3k

Mr. Joseph Lucchese (Age 55)
Exec. VP, CFO, Treasurer & Sec.
Comp: $378.07k

Dr. Alan Mendelsohn M.D. (Age 59)
Exec. VP & Chief Medical Officer
Comp: $450.73k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TMBR Stock - Frequently Asked Questions

Should I buy or sell Timber Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Timber Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TMBR shares.
View TMBR analyst ratings or view top-rated stocks.
What is Timber Pharmaceuticals' stock price forecast for 2022?: 1 equities research analysts have issued 1 year price objectives for Timber Pharmaceuticals' shares. Their TMBR share price forecasts range from $1.00 to $1.00. On average, they predict the company's share price to reach $1.00 in the next twelve months. This suggests a possible upside of 941.7% from the stock's current price.
View analysts price targets for TMBR or view top-rated stocks among Wall Street analysts.
How have TMBR shares performed in 2022?: Timber Pharmaceuticals' stock was trading at $0.38 on January 1st, 2022. Since then, TMBR stock has decreased by 74.7% and is now trading at $0.0960.
View the best growth stocks for 2022 here.
When is Timber Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our TMBR earnings forecast.

How were Timber Pharmaceuticals' earnings last quarter?: Timber Pharmaceuticals, Inc. (NYSE:TMBR) announced its quarterly earnings results on Thursday, August, 11th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.05. Timber Pharmaceuticals had a negative trailing twelve-month return on equity of 228.75% and a negative net margin of 1,274.17%.
What is Timber Pharmaceuticals' stock symbol?: Timber Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "TMBR."
How do I buy shares of Timber Pharmaceuticals?: Shares of TMBR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Timber Pharmaceuticals' stock price today?: One share of TMBR stock can currently be purchased for approximately $0.10.
How much money does Timber Pharmaceuticals make?: Timber Pharmaceuticals (NYSE:TMBR) has a market capitalization of $12.72 million and generates $890,000.00 in revenue each year. The company earns $-10,640,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis.
How can I contact Timber Pharmaceuticals?: Timber Pharmaceuticals' mailing address is 50 TICE BLVD SUITE A26, WOODCLIFF LAKE NJ, 07677. The official website for the company is www.timberpharma.com. The company can be reached via phone at (914) 205-3481 or via email at sprince@pcgadvisory.com.

This page (NYSE:TMBR) was last updated on 10/5/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Timber Pharmaceuticals - TMBR Stock Forecast, Price & News

Timber Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Timber Pharmaceuticals (NYSE:TMBR) Stock

TMBR Stock News Headlines

TMBR Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

TMBR Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™